Keywords
How to Cite
Abstract
Stereotactic body radiation therapy currently occupies its place in the complex treatment of cancer patients with liver metastases. It is assumed that certain groups of patients with breast cancer can benefit from the use of this method, which can be converted into improved overall survival and survival rates without signs of progression of the process. Purpose of the study was to evaluate the efficacy and tolerability of stereotactic radiotherapy in patients with breast cancer metastases in the liver. We have analyzed the results of using stereotactic radiotherapy in 25 breast cancer patients with 43 liver metastases. The treatment was carried out in 3 fractions with a fraction dose of 10-15 Gy and a total dose of 30-45 Gy. Growth of the irradiated lesions was recorded only in 1 case out of 43 metastases (2,3%) and 25 (4%) patients. 1-, 3- and 5-year overall survival rates from the moment of stereotactic radiotherapy were 82,9%, 62% and 38,7%, respectively. Long-term post-radiation adverse events were observed in 8% of cases and did not have a significant effect on the quality of life and the possibility of antitumor treatment. So stereotactic radiotherapy can be recommended as a relatively safe and highly effective method of elimination of breast cancer liver metastases. Taking into account the high achieved local control, further studies on dose escalation in this group of patients are not required.
References
Guckenberger M, Lievens Y, Bouma AB et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation // Lancet Oncol. 2020 Jan; 21(1):e18-e28. PMID: 31908301. https: // doi: 10.1016/S1470-2045(19)30718-1
Salama JK, Chmura AJ. The role of surgery and ablative radiotherapy in oligometastatic breast cancer // Semin Oncol 2014 Dec;41(6):790-7. https: // doi: 10.1053/j.seminoncol.2014.09.016.
Buzdar AU, Blumenschein GR, Montague ED et al. Combined modality approach in breast cancer with isolated multiple metastases // Am J Clin Oncol. 1984 Feb;6:45–50. PMID: 6364779. https: // doi: 10.1097/00000421-198402000-00006.
Milano MT, Katz AW, Muhs AG et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions // Cancer. 2008 Feb;112(3):650–658. PMID: 18072260. https: // doi: 10.1002/cncr.23209.
Milano MT, Zhang H, Metcalfe SK et al. Oligometastatic breast cancer treated with curative intent stereotactic body radiation therapy // Breast Cancer Res Treat. 2009;115:601–8. https: // doi: 10.1007/s10549-008-0157-4.
Milano MT, Katz AW, Zhang H et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study // Int J Radiat Oncol Biol Phys. 2011;83:878–86.
Abbott DE, Brouquet A, Mittendorf EA et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome // Surgery. 2012;151:710–16. https: // doi: 10.1016/j.surg.2011.12.017
Tree AC, Khoo VS, Eeles RA et al. Stereotactic body radiotherapy for oligometastases // Lancet Oncol. 2013;14: e28–37. https: // doi: 10.4172/2155-9619.1000155.
Weykamp F, König L, Seidensaal K et al. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer // Front. Oncol., 26 June 2020. https: // doi: org/10.3389/fonc.2020.00987
Lewis S, Porceddu S, Nakamura N et al. Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >100herapy: long-term follow-up of prospective study // Int J Radiat Oncol Biol Phys. 2011;83:878–86. https: // doi: https://doi.org/10.1097/COC.0000000000000169
Scorsetti M, Franceschini D, Rose FD et al. The role of SBRT in oligometastatic patients with liver metastases from breast cancer // Reports of practical oncology and radiotherapy. 22(2017):163–169. https: // doi: 10.1016/j.rpor.2016.07.008
Onal C, Guler OC, Yildirim BA. Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy // The Breast. 42 (2018):150e156 https: // doi: org/10.1016/j.breast.2018.09.006
https://www.postersessiononline.eu/pr/aula_poster.asp?congreso=383449733
Romero AM, Keskin-Cambay F, van Os RM et al. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Reports of Practical Oncology and Radiotherapy // Rep Pract Oncol Radiother. Mar-Apr 2017; 22(2):126–131. https: // doi: 10.1016/j.rpor.2016.10.003
Doi H, Uemoto K, Suzuki O et al. Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer // Oncol Lett. 2017;14:453–460. https: // doi: 10.3892/ol.2017.6167
Jingu K, Matsushita H, Yamamoto T et al. Stereotactic Radiotherapy for Pulmonary Oligometastases From Colorectal Cancer: A Systematic Review and Meta-Analysis // Technol Cancer Res Treat. 2018;17. https: // doi: 10.1177/1533033818794936
Cao C, Wang D, Tian DH et al. A systematic review and meta-analysis of stereotactic body radiation therapy for colorectal pulmonary metastases // J Thorac Dis. 2019 Dec;11(12):5187–5198. https: // doi: 10.21037/jtd.2019.12.12
Wegner RE, Ahmed N, Hasan S et al. Stereotactic body radiotherapy for lung metastases from colorectal cancer: a single institution experience // Colorectal Cancer. 2018;7(3). https: // doi: org/10.2217/crc-2018-0005
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021